Trial Profile

A real-world study of brivaracetam in US

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 27 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brivaracetam (Primary) ; Carbamazepine; Lamotrigine; Levetiracetam; Oxcarbazepine
Indications Epilepsy; Partial epilepsies
Focus Adverse reactions; Therapeutic Use

Most Recent Events

26 Apr 2022 Results of post-hoc analysis assessing long-term real-world effectiveness and tolerability of brivaracetam (BRV) in adults with focal seizures, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
24 Jun 2020 According to a UCB media release, Baseline Seizure Related Disability Assessment Scale (SERDAS) scores data from this trial published in the online supplement to Neurology.
24 Jun 2020 According to a UCB media release, Baseline Seizure Related Disability Assessment Scale (SERDAS) scores data from this trial available online via the 2020 AAN Science Highlights virtual platform.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com